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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER2051In-Stent Neoatherosclerosis as Mechanism of Late Stent FailureSeung-Jung Park, Soo-Jin Kang, Renu Virmani, Masataka Nakano, Yasunori Ueda
Drug-eluting stents (DES) have reduced, but not eliminated, the risk of in-stent restenosis
(ISR) associated with bare-metal stents (BMS). Although ISR of BMS was considered a
stable slow-growing problem, recent studies have reported that 1 of 3 of patients with ISR
present with acute coronary syndromes. Park and colleagues review this data as well as clinical
and histologic studies of DES which demonstrate evidence of continuous neointimal growth
during long-term follow-up. Evidence of de novo neoatherosclerosis has been found on
histology, angioscopy, and intravascular images. This in-stent neoatherosclerosis is an
important substrate for late stent failure for both BMS and DES, especially during long-term
follow-up.VIEWPOINT AND COMMENTARY VIEWPOINT AND COMMENTARYNiacin and Statin Combination Therapy After AIM-HIGH2058Erin D. Michos, Christopher T. Sibley, Jefferson T. Baer, Michael J. Blaha, Roger S. Blumenthal
2065Stephen J. Nicholls
The AIM-HIGH trial, which compared combined niacin/simvastatin to simvastatin alone,
failed to demonstrate an incremental benefit of niacin among patients with atherosclerotic
cardiovascular disease and on-treatment low-density lipoprotein cholesterol values 70 mg/dl.
Michos and colleagues review the epidemiologic evidence supporting the use of niacin to raise
high-density lipoprotein cholesterol (HDL-C) and previous, smaller trials of niacin plus
statins showing regression of carotid atherosclerosis. This viewpoint summarizes these trials
and describes limitations in study design that may explain the failure of AIM-HIGH to
support the HDL-C raising hypothesis. An accompanying editorial by Nicholls, further
explores the clinical implications of AIM-HIGH and the challenges of further reducing
cardiac risk in patients on optimal statin-therapy.(continued on page A-21)
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tINTERVENTIONAL CARDIOLOGY2068MR Associated With Higher Early, But Not Late Mortaliy, After TAVRStefan Toggweiler, Robert H. Boone, Josep Rodés-Cabau, Karin H. Humphries, May Lee,
Luis Nombela-Franco, Rodrigo Bagur, Alexander B. Willson, Ronald K. Binder, Ronen Gurvitch,
Jasmine Grewal, Robert Moss, Brad Munt, Christopher R. Thompson, Melanie Freeman, Jian Ye,
Anson Cheung, Eric Dumont, David A. Wood, John G. Webb
Toggweiler and colleagues explored the influence of baseline mitral regurgitation (MR) on
clinical outcomes following transcatheter aortic valve replacement (TAVR). Patients with
moderate/severe MR had a higher mortality rate than patients with  mild MR during the
30 days following TAVR (adjusted HR: 2.10). However, the mortality rate after 30 days was
similar (adjusted HR: 0.82). One year following TAVR, moderate MR had improved in
58%, worsened to severe in 1%, and 24% of patients had died. Severe MR had improved in
49%, and 35% of patients had died. Moderate or severe MR in patients undergoing TAVR is
associated with a higher early, but not late, mortality rate.HEART RHYTHM DISORDERS2075Risk Score Predicts Benefit of ICD at 8 YearsAlon Barsheshet, Arthur J. Moss, David T. Huang, Scott McNitt, Wojciech Zareba, Ilan Goldenberg
Barsheshet and colleagues used data from the MADIT-II study to determine if a simple risk
score could identify those likely to benefit from nonresynchronization implantable
cardioverter-defibrillator (ICD) therapy at 8 years. The previously developed risk score
included 5 clinical factors (New York Heart Association functional class II, age 70 years,
lood urea nitrogen 26 mg/dl, QRS duration 0.12 s, and atrial fibrillation). Patients with
ow (0 risk factors) and intermediate risk (1 to 2 risk factors) had significantly higher
robability of survival at 8 years when treated by ICD as compared with medical therapy.
he risk of death at 8 years among high-risk patients (3 or more risk factors) was high and
ot different between the ICD and non-ICD subgroups. These findings suggest that a simple
isk score can identify patients who derive significant long-term benefit from primary ICD
herapy.CARDIAC IMAGING2080Diabetes Associated With Increased Carotid Wall 18F-FDG-PET UptakeJan Bucerius, Venkatesh Mani, Colin Moncrieff, James H. F. Rudd, Josef Machac, Valentin Fuster,
Michael E. Farkouh, Zahi A. Fayad
Inflammation is a pivotal process in the progression of atherosclerosis, which can be non-
invasively imaged by 18F-fluorodeoxyglucose positron emission tomography (FDG-PET). In
this study, Bucerius and colleagues studied the impact of diabetes on carotid wall FDG
uptake. There was a significant association between diabetes and FDG uptake in the arterial
wall when the FDG uptake was corrected for the pre-scan glucose level. Correcting for the
glucose level has been proposed as a method to correct for elevated serum glucose diluting the
uptake of the fluorodeoxyglucose tracer and may explain the failure of previous studies to find
an association.Editorial Comment: John O. Prior, page 2089
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JUNE 5, 2012 (continued) A-22BIOMARKERS2091A 2-Hour Accelerated Diagnostic Protocol for Patients With Chest PainMartin Than, Louise Cullen, Sally Aldous, William A. Parsonage, Christopher M. Reid, Jaimi Greenslade,
Dylan Flaws, Christopher J. Hammett, Daren M. Beam, Michael W. Ardagh, Richard Troughton,
Anthony F. T. Brown, Peter George, Christopher M. Florkowski, Jeffrey A. Kline, W. Frank Peacock,
Alan S. Maisel, Swee Han Lim, Arvin Lamanna, A. Mark Richards
Than and colleagues sought to determine whether an accelerated diagnostic protocol (ADP)
for patients with chest pain could identify low-risk patients suitable for early discharge. This
prospective, observational study tested an ADP, which included, pre-test probability scoring
by the TIMI score, electrocardiograph, and 0 and 2 hour values of troponin I. The primary
endpoint was major adverse cardiac event (MACE) within 30 days. The ADP classified 20% of
patients as low risk. One (0.25%) of these 392 low-risk patients had a MACE, giving the ADP a
sensitivity of 99.7%. These results suggest that it is safe to discharge chest pain patients with a
normal electrocardiogram, a TIMI score of 0, and nonelevated troponin I at 0 and 2 hours.Editorial Comment: Erik P. Hess, Allan S. Jaffe, page 2099CONGENITAL HEART DISEASE
2101Outcome of Cardiac Surgery in Patients Older Than 50 Years of Age
With Ebstein AnomalyChristine H. Attenhofer Jost, Heidi M. Connolly, Christopher G. Scott, Harold M. Burkhart,
Carole A. Warnes, Joseph A. Dearani
Attenhofer Jost and colleagues analyzed presentation, surgical procedures, and outcomes in
patients older than 50 years with Ebstein anomaly (EA) who underwent surgery. Of the 81
older patients with EA underwent cardiac surgery at the Mayo Clinic, 85% had functional
class III or IV symptoms. Tricuspid valve surgery was necessary in 98% of the procedures:
replacement in 3 of 4 patients and repair in 1 of 4 patients. Three early deaths occurred (4%).
On long-term follow-up, 89% had improved functional class and the 20-year survival was
65%. These results show that although cardiac surgery in patients with EA older than
50 years is often complex, early mortality is low (4%) and long-term survival is good.PRE-CLINICAL RESEARCH PRE-CLINICAL RESEARCH2107Altered Micro-RNA Expression Impairs the Survival of BMC After Myocardial InfarctionQuanfu Xu, Florian H. Seeger, Jessica Castillo, Kazuma Iekushi, Reinier A. Boon, Ruxandra Farcas,
Yosif Manavski, Yi-Gang Li, Birgit Assmus, Andreas M. Zeiher, Stefanie Dimmeler
Xu and colleagues investigated the regulation and function of micro-RNAs in bone marrow
mononuclear cells (BMC) from patients with and without previous myocardial infarction. Small
noncoding micro-RNAs post-transcriptionally control gene expression patterns and play a crucial
role in modulating cell survival and function. Several micro-RNAs were found to be up-regulated
after myocardial infarction, including the pro-apoptotic and anti-proliferative miR-34a and the
hypoxia-controlled miR-210. Pre-treatment of BMC to block the effect of miR-34a significantly
increased the therapeutic benefit of transplanted BMC in a mouse model. These results demon-
strate that myocardial infarction significantly alters the miR expression of BMC in humans and
targeting this may improve the therapeutic benefit of cell therapy.
